<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59102">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336594</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-110</org_study_id>
    <nct_id>NCT02336594</nct_id>
  </id_info>
  <brief_title>RDEA3170 Bioavailability Study</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Two RDEA3170 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and
      pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative
      bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets)
      and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat
      and high-fat meal on the PK and PD of RDEA3170 10 mg tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile and relative bioavailability of RDEA3170 tablets</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Serial plasma PK samples will be collected up to 72 hours postdose on Day 1 and Day 5
PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); apparent terminal half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of low-fat meal on PK profile of RDEA3170 from plasma</measure>
    <time_frame>Days 1 to 9</time_frame>
    <description>Serial plasma PK samples will be collected up to 72 hours postdose on Days 1 to 9
PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); apparent terminal half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of high-fat meal on PK profile of RDEA3170 from plasma</measure>
    <time_frame>Days 1 to 13</time_frame>
    <description>Serial plasma PK samples will be collected up to 72 hours postdose on Days 1 to 13
PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); apparent terminal half-life (t1/2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Dose PD Profile of RDEA3170 from serum and urine</measure>
    <time_frame>Day -1 to Day 13</time_frame>
    <description>Serial serum PD samples will be collected up to 24 hours postdose on Days -1, 1, 5, 9 and 13.
Urine PD samples will be collected at various intervals within 24 hours postdose on Days -1, 1, 5, 9 and 13.
PD endpoints in terms of serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of RDEA3170</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 10 mg</intervention_name>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_label>Sequence BADC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 2.5 mg</intervention_name>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_label>Sequence BADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved and is
             willing to provide written informed consent before the first study-related activity

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2

          -  Subject has a Screening serum urate level ≤ 7 mg/dL

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment

        Exclusion Criteria:

          -  Subject has a history or suspicion of kidney stones

          -  Subject has undergone major surgery within 3 months prior to Screening

          -  Subject donated blood or experienced significant blood loss (&gt; 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture

          -  Subject has a Screening serum creatinine value above the upper limit of normal during
             Screening or at Day -2 (Admission)

          -  Subject cannot swallow multiple tablets

          -  Subject is a heavy caffeine drinker

          -  Subject is unwilling to comply with the dietary restrictions of the study

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 10, 2015</lastchanged_date>
  <firstreceived_date>November 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
